Jasper Therapeutics to Present at Upcoming Investor Conferences
RBC Capital Markets 2025 Global Healthcare Conference Conference Dates: May 20-21, 2025Presentation Date/Time: Wednesday, May 21, 2025; 11:00 a.m. EDTPresentation Format: Fireside Chat
Jefferies 2025 Global Healthcare ConferenceConference Dates: June 3-5, 2025Presentation Date/Time: Thursday, June 5, 2025; 11:40 a.m. EDTPresentation Format: Presentation
Live webcasts of the presentations will be available on the News & Events – Events page of Jasper's Investor Relations website. An archived replay of each presentation will be available on Jasper's website for 30 days following the applicable live broadcast.
About Jasper
Jasper is a clinical-stage biotechnology company focused on developing briquilimab as a therapeutic for chronic mast cell diseases. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor KIT, thereby inhibiting signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of the inflammatory response in mast cell driven diseases such as chronic urticaria and asthma. Jasper is currently conducting clinical studies of briquilimab as a treatment in patients with CSU, CIndU or asthma. Briquilimab has a demonstrated efficacy and safety profile in patients and healthy volunteers, with positive clinical outcomes in CSU and CIndU. For more information, please visit us at www.jaspertx.com.
Forward-Looking Statements
Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'should,' 'would,' 'plan,' 'predict,' 'potential,' 'seem,' 'seek,' 'future,' 'outlook' and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab's potential, including with respect to its potential in mast cell driven diseases such as CSU, CIndU, and asthma; and Jasper's participation in the RBC Capital Markets 2025 Global Healthcare Conference and the Jefferies 2025 Global Healthcare Conference. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that prior test, study and trial results may not be replicated in continuing or future studies and trials; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper's product candidates may not be beneficial to patients or successfully commercialized; patients' willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper's business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper's business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper's assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Contacts:
Alex Gray (investors)Jasper Therapeutics650-549-1454 agray@jaspertherapeutics.com
Joyce Allaire (investors)LifeSci Advisors617-435-6602jallaire@lifesciadvisors.com
Lauren Walker (media)Real Chemistry646-564-2156lbarbiero@realchemistry.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
Apple crushes earnings expectations, but stays mum on a major asset
Apple crushes earnings expectations, but stays mum on a major asset originally appeared on TheStreet. Apple (Nasdaq: AAPL) reported its third-quarter earnings on July 31, beating Wall Street expectations on almost every front — from profit and revenue to iPhone sales and gross margins. The tech giant posted earnings per share (EPS) of $1.57, well above the expected $1.43, and $94.04 billion in revenue, exceeding forecasts of $89.53 billion. This marks Apple's largest quarterly revenue growth since December 2021. 'It was an exceptional quarter by any measure,' said CEO Tim Cook, speaking to CNBC after the report dropped. Apple's most important business — the iPhone — led the charge. iPhone revenue surged 13% year-over-year to $44.58 billion, boosted in part by strong sales of the iPhone 16, which Cook said saw 'strong double-digit' growth over its predecessor. Investors are keeping an eye on the tech behemoth for another reported addition. A new Fortune report revealed that Apple is in early discussions with fellow tech giants Airbnb and Google to introduce stablecoins, aiming to bring them into the mainstream for facilitating cross-border payments and reducing trading costs. Stablecoins could enable Apple to maximize transaction fees around the world, sources say — an indication that the technology company is making bigger moves into digital finance. Analysts, however, are not expecting a huge revenue boost, as Trump has threatened a 25% tax on iPhones unless they are made in the US, resulting in margin pressure on quarter three and quarter also has uncertainty around its $20 billion-per-year agreement with Google, which is at risk as a judge considers how to rule in the DOJ's antitrust case, as per reports. Reports also mention analysts like BofA's Wamsi Mohan say the attention will be on margin performance and iPhone revenue, which they see rising slightly to $39.8 billion. While Apple has not directly entered the crypto industry, it has eased up previous restrictions on crypto applications. Further, as of May, Apple Pay also supports stablecoin transactions with payment service provider, Mesh. The integration allows consumers to spend USDC and USDT at checkout and convert them to fiat in real-time. Apple crushes earnings expectations, but stays mum on a major asset first appeared on TheStreet on Jul 31, 2025 This story was originally reported by TheStreet on Jul 31, 2025, where it first appeared.
Business Wire
2 hours ago
- Business Wire
LINE Investors Have Opportunity to Lead Lineage, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Lineage, Inc. ('Lineage' or 'the Company') (NASDAQ: LINE) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's Offering Documents issued in connection with its initial public offering ('IPO') conducted in July 2024, are encouraged to contact the firm before September 30, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Lineage suffered a weakening of demand as customers destocked excessive inventory and adjusted their businesses to changing consumer trends. The Company raised prices leading up to the IPO in an unsustainable manner. The Company failed to counteract its demand problems through marketing or its supposed competitive advantages. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Lineage, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Miami Herald
2 hours ago
- Miami Herald
Lamborghini's First Personalized Temerario Glows in Grey and Blue
Lamborghini's shift toward electrified supercars continues with the introduction of the Temerario, the Italian marque's all-new plug-in hybrid coupe. The model represents the brand's departure from the Huracán and its long-serving V10 engine, which has been replaced by a more potent and efficient twin-turbo V8 hybrid setup. With the Temerario, Lamborghini completes its transition to a fully electrified product line alongside the Revuelto and the Urus SE. The latest development comes in the form of the first Temerario Ad Personam – a fully customized one-off model created by Lamborghini's personalization division. Revealed in Porto Cervo, Sardinia, during a private gathering, the build draws inspiration from the Mediterranean backdrop and introduces a tailored visual expression of the new hybrid Lamborghini. Dubbed the Temerario Porto Cervo, this one-off example is defined by a finish called Grigio Serget – a grey base that reveals embedded blue flakes under direct light. Gloss black elements in Nero Noctis outline the lower body, front splitter, rear diffuser, and side scoops. A slim pinstripe in Blu Royal provides a color break across the body, also found on the rear wing. Blue brake calipers hide behind Velador gloss black wheels, and matte black quad tailpipes add contrast at the rear. Inside, the blue-grey theme continues. Grigio Octans leather and Corsa Tex upholstery form the base of the cabin, while Blu Nethuns stitching and leather inserts appear across seat panels and door trims. Embroidery includes Lamborghini logos and a Temerario script with Tricolore detail along the cabin's rear wall. A profile of the car is stitched into the doors, while matte carbon trim and a red-detailed carbon steering wheel reinforce the supercar's driver-oriented purpose. Two plaques mark this unit's uniqueness: one reads Ad Personam on the driver-side B-pillar, the other tagged "Porto Cervo 2025" – to be replaced by the owner's custom plate before delivery. The Temerario is powered by an all-new 4.0-liter twin-turbo V8 engine paired with three electric motors. The gasoline engine alone delivers 789 hp with a 10,000 rpm redline. With hybrid assistance, total output reaches 907 hp. Power is routed to all four wheels via an 8-speed dual-clutch automatic. Lamborghini claims 0–100 km/h in 2.7 seconds and a top speed of 213 mph. The Temerario Porto Cervo is a one-off commission, though Lamborghini's Ad Personam program allows buyers to create similarly bespoke configurations. The standard model's MSRP hovers around $300,000. Production takes place alongside the Revuelto on Lamborghini's new hybrid-capable line in Sant'Agata Bolognese. Copyright 2025 The Arena Group, Inc. All Rights Reserved.
